Journal Article

Epidemiology, Appropriateness, and Cost of Vancomycin Use

William R. Jarvis

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 26, issue 5, pages 1200-1203
Published in print May 1998 | ISSN: 1058-4838
Published online May 1998 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/520284
Epidemiology, Appropriateness, and Cost of Vancomycin Use

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Pharmaceutical costs, which approach $40 billion annually, account for about 8% of health care costs. Prescription drugs represent 5% to 20% of the total hospital budget, and antimicrobials account for 20% to 50% of hospital pharmaceutical costs. At one university hospital, the percentage of patients receiving antimicrobials increased from 31.8% in 1988 to 53.1% in 1994. Receipt of vancomycin has been associated with the emergence of resistant enterococci and has resulted in Centers for Disease Control and Prevention (CDC) recommendations for its use. Studies show that vancomycin use is increasing, that dosing is often inappropriate, that certain populations (such as oncology, neurosurgery, and cardiovascular surgery patients) are more likely to receive vancomycin, and that often use is not consistent with CDC recommendations. Few studies have assessed the cost of vancomycin use; those that have show that it is costly. Further studies of vancomycin use are needed, so that use can be improved through focused educational programs.

Journal Article.  0 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.